Targeting LAG-3 to Potentiate Antitumor Immune Activity: Expert Guidance on Molecular Function and Clinical Application

Download All

This series of live workshops will cover the importance of LAG-3 as a new immunotherapy target and the emerging data on the mechanism of action, use, and safety of anti–LAG-3 immunotherapies across a range of malignancies. Accompanying these workshops will be a downloadable slideset, simulcasts, an expert commentary, a PDF practice resource, and an on-demand webcast.

Live webinars!

Webinar 1 - June 28, 2022

Webinar 2 - July 6, 2022

Webinar 3 - July 19, 2022

 

Evan J. Lipson, MD

ClinicalThought

In this commentary, Dr. Evan Lipson reviews LAG-3 as a therapeutic target and discusses evidence from the RELATIVITY-047 trial of the combination of the anti–LAG-3 antibody relatlimab plus nivolumab as first-line therapy in advanced melanoma.

Evan J. Lipson, MD Released: March 21, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings